Effect of protease inhibitors (indinavir and ritonavir) on the pharmacokinetics of gliclazide in rabbits

References

• Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000;31:1467–1475.
   PubMed Web of Science ®Google Scholar
• Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir ImmuneDefic Syndr. 2009;50(5):499–505.
   Web of Science ®Google Scholar
• Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease- inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–2099.
   PubMed Web of Science ®Google Scholar
• Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;141:782–787.
   Google Scholar
• Satyanarayana S, Kumar EK. Influence of nicorandil on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Mol CellBiochem. 2006;291:101–105.
   Web of Science ®Google Scholar
• Mastan SK, Chaitanya G, Reddy KR, Kumar KE. An appraisal to the special sulphonylurea: gliclazide. Pharmacologyonline. 2009;1:254–269.
   Google Scholar
• Schernthaner G. Gliclazide modified release: a critical review of pharmacodynamic, metabolic and vasoprotective effects. Metabolism. 2003;52:29–34.
   PubMed Web of Science ®Google Scholar
• Mastan SK, Kumar KE. Effect of indinavir on the pharmacodynamic activity of gliclazide in rats and rabbits. Int J Integr Biol. 2009;7:16–21.
   Google Scholar
• Mastan SK, Kumar KE. Influence of ritonavir on the pharmacodynamics of gliclazide in animal models. Diabetologia Croat. 2009;38:105–113.
   Google Scholar
• Mastan SK, Kumar KE. Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose-insulin homeostasis in animal models. J Exp Pharmacol 2010;2:1–11.
   Google Scholar
• Lawrence DR, Bacharach AL, editors. Evaluation of Drug Activities: Pharmacometrics. New York, NY: Academic Press; 1964.
   Google Scholar
• Hruz PW. Molecular mechanisms for altered glucose homeostasis in HIV infection. Am J Infect Dis. 2006;2:187–192.
   Google Scholar
• Gupta RC, Atul BV Drug metabolism studies in animal models. Ind J Pharmacol. 2000;32:S62-S66.
   Google Scholar
• Lin JH. Species similarities and differences in pharmacokinetics. Drug Metab Dispos. 1995;23:1008–1021.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40:159–168.
   PubMed Web of Science ®Google Scholar
• Chiba M, Nishime JA, Neway W, Lin Y, Lin JH. Comparative in vitro metabolism of indinavir in primates - a unique stereoselective hydroxylation in monkey. Xenobiotica. 2000;30(2):117–129.
   Web of Science ®Google Scholar
• Nakamura T, Okada K, Nagata K, Yamazoe Y. Intestinal cytochrome P450 and response to rifampicin in rabbits. Jpn J Pharmacol. 2000;82:232–239.
   PubMedGoogle Scholar
• Jasinska M, Owczarek J, Orszulak-Michalak D. Influence of simvastatin at high dose and nifedipine on hemodynamic parameters in rabbits. Pharmacological Reports. 2006;58:48–59.
   Web of Science ®Google Scholar
• Fang HM, Xu JM, Mei Q, et al. Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. Acta Pharmacol Sin. 2009;30:1566–1572.
   PubMed Web of Science ®Google Scholar
• Satyanarayana S, Kumar KE, Rajasekhar J, Thomas L, Rajanna S, Rajanna B. Influence of aqueous extract of fenugreek-seed powder on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits. Therapy. 2007;4:457–463.
   Google Scholar
• Kumar KE, Ramesh A, Satyanarayana S. Pharmacodynamic and pharmacokinetic drug interaction of gliclazide and lacidipine in animal models. Ind J Pharm Educ Res. 2008;42:277–282.
   Web of Science ®Google Scholar
• Pichard L, Gillet G, Fabre I, et al. Identification of the rabbit and human cytochromes P-450 IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab Dispos. 1990;18:711–719.
   PubMed Web of Science ®Google Scholar
• Sinko PJ, Kunta JR, Usansky HH, Perry BA. Differentiation of gut and hepatic first pass metabolism and secretion of saquinavir in ported rabbits. J Pharmacol Exp Ther. 2004;310:359–366.
   Web of Science ®Google Scholar
• Yeung PK, Mosher SJ, Pollak PT. Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration. Eur J Drug Metab Pharmacokinet. 1991;16:69–74.
   Web of Science ®Google Scholar
• Campbell DB, Lavielle R, Nathan C. The mode of action on clinical pharmacology of gliclazide a review. Diabetes Res Clin Pract. 1991;14:S21-S36.
   PubMed Web of Science ®Google Scholar
• Wajchenberg BL, Santomano ATMG, Porrelli RN. Effect of sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose mediated, glucose disposal in patients with non-insulin dependent diabetes mellitus (NIDDM). Diabetes Res Clin Pract. 1993;20:147–154.
   Web of Science ®Google Scholar
• Product monograph. PrDIAMICRON® Gliclazide 80 mg tablets. Hypoglycemic sulfonylurea Oral hypoglycemic agent. SERVIER CANADA Inc. [Date of Revision: 2009 Jan 15. Pages 1–27]. http://webprod.hc-sc.gc.ca/dpd-bdpp/item-iteme.do?pm-mp=00007471
   Google Scholar
• Rollins DE, Klaassen CD. Biliary excretion of drugs in man. Clin Pharmacokinet. 1979;4:368–379.
   PubMed Web of Science ®Google Scholar
• Davis TME, Daly F, Walsh JP, et al. Pharmacokinetics and pharmacodynamics of gliclazide in caucasians and Australian aborigines with type 2 diabetes. Br J Clin Pharmacol. 2000;49:223–230.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [home page on the Internet]. FDA approved drug products: CRIXIVAN® (Indinavir sulfate) Capsules Label; [issued 2010 April 26; cited 2010 Oct 28]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020685s071lbl.pdf
   Google Scholar
• Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome p4503a4/3a5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Disp. 1998;26:552–561.
   PubMed Web of Science ®Google Scholar
• Lin JH, Chiba M, Balani SK, et al. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos. 1996;24:1111–1120.
   PubMed Web of Science ®Google Scholar
• Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001;15:F11-F18.
   PubMed Web of Science ®Google Scholar
• Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans:a randomized, placebocontrolled study. AIDS. 2002;16(5):F1-F8.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration [home page on the Internet]. FDA approved drug products: NORVIR® (Ritonavir) Tablets Label; [issued 2010 Apr 27; cited 2010 Oct 28]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020659s050,022417s001 lbl.pdf
   Google Scholar
• Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther. 1996;277:423–431.
   PubMed Web of Science ®Google Scholar
• Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos.1996;24:307–314.
   Google Scholar
• Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos. 1998;26:552–561.
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35:275–291.
   PubMed Web of Science ®Google Scholar
• Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol. 1998;38:106–111.
   PubMed Web of Science ®Google Scholar
• Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol. 1997;44:190–194.
   PubMed Web of Science ®Google Scholar
• Oida T, Yoshida K, Kagemoto A, Sekine Y, Higashijima T. The metabolism of gliclazide in man. Xenobiotica. 1985;15:87–96.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Launay-Vacher V, Deray G. Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis. Nephrol Dial Transplant. 2001;16:643.
   Web of Science ®Google Scholar
• Singh R, Chang SY, Taylor LCE. In vitro metabolism of a potent HIV- protease inhibitor (141W94) using rat, monkey and human liver S9. Rapid Commun Mass Spectrom. 1996;10:1019–1026.
   PubMed Web of Science ®Google Scholar
• Eagling VA, Wiltshire H, Whitcombe IWA, Back DJ. CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica. 2002;32:1–17.
   PubMed Web of Science ®Google Scholar
• Kumar GN, Jayanti V, Lee RD, Whittern DN, Uchic J, Thomas S, et al. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos. 1999;27:86–91.
   PubMed Web of Science ®Google Scholar
• Sevrioukovaa IF, Poulosa TL. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA. 2010;107:18422–18427.
   Web of Science ®Google Scholar
• Lin JH, Chiba M, Chen IW, et al. Time- and dose-dependent pharmacokinetics of L-754,394, an HIV protease inhibitor, in rats, dogs and monkeys. J Pharmacol Exp Ther. 1995;274:264–269.
   PubMed Web of Science ®Google Scholar
• Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos. 1998;26:257–260.
   PubMed Web of Science ®Google Scholar
• Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol. 1997;44:190–194.
   PubMed Web of Science ®Google Scholar
• Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. Biol Psychiatry. 2000;47:655–661.
   PubMed Web of Science ®Google Scholar